Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriatic arthritis

New and Updated Patient Education Materials Available

Staff  |  January 1, 2007

The ACR is continually updating and increasing its collection of patient education materials, or fact sheets. One of the newest fact sheets, “Pregnancy and Rheumatic Disease,” discusses the complex interactions of pregnancy and rheumatic diseases, acceptable medications to use during pregnancy and breastfeeding and helps to define what constitutes a high-risk pregnancy. The fact sheet offers links to additional resources and educational materials.

Filed under:Education & TrainingFrom the College Tagged with:AC&REducationpatient carePatient Fact SheetTechnology

A Primer on Imaging in Myositis

Rochelle Castillo, MD, MS, Andro Licaros, MD, & Jemima Albayda, MD  |  November 9, 2022

In medicine, as in advertising, pictures can be worth a thousand words. From arthritis to vasculitis, imaging studies have been variably employed to aid in the diagnosis, treatment, risk stratification and prognostication of patients with rheumatic and musculoskeletal disorders. The same holds true with the idiopathic inflammatory myopathies (IIM), in which the clinical utility is…

Filed under:ConditionsMyositis Tagged with:dermatomyositisMagnetic resonance imaging (MRI)myositispositron emission tomography (PET)Ultrasound

Changing Treatment Patterns for Patients with JIA

Lara C. Pullen, PhD  |  October 18, 2022

A study from Glerup et al. demonstrated that many patients with juvenile idiopathic arthritis achieved drug-free remission over 18 years of follow-up and that remission rates remained stable between years 8 and 18 of the study period.

Filed under:ConditionsPediatric ConditionsResearch RheumRheumatoid Arthritis Tagged with:ChildrenILARJIAjuvenile idiopathic arthritis (JIA)Pediatric

Stmool / shutterstock.com

How to Avoid Cognitive Errors in Rheumatology

Megan Milne, MD, & Rebecca E. Sadun, MD, PhD  |  March 14, 2022

The 1999 Institute of Medicine report To Err Is Human gave a sobering depiction of the magnitude and consequences of medical error.1 The report concluded that approximately 98,000 people die in hospitals annually due to preventable medical errors. Of all the errors detailed in this report, diagnostic errors have since been determined to be the…

Filed under:Professional Topics Tagged with:best practicesbiascognitive errorsErrorsmedical errors

A Possible Diagnostic Tool: RheumMadness 2022 AI: JIA Subtypes Scouting Report

The Children’s Hospital at Montefiore Pediatric Rheumatology Fellowship Program: Alisha Akinsete, MD; Malki Peskin, MD; & Jessica Perfetto, MD  |  February 14, 2022

Machine learning is a tool that may help pediatric rheumatologists distinguish between different subtypes of juvenile idiopathic arthritis (JIA) and predict treatment response.

Filed under:ConditionsResearch Rheum Tagged with:AIartificial intelligenceenthesitis-related arthritisJIAjuvenile idiopathic arthritis (JIA)RheumMadnessTechnology

Reproductive Health, Beyond the Guidelines: Rheumatologists Must Think About Patients’ Psychosocial Needs

Mary Beth Nierengarten  |  January 25, 2021

Experts discuss how rheumatologists must consider the psychosocial aspect of care in the decision-making process for women when addressing their reproductive health needs, in addition to medication safety.

Filed under:ACR ConvergenceConditionsMeeting Reports Tagged with:ACR Convergence 2020Association of Rheumatology Professionals (ARP)biopsychosocialpatient carepregnancypsychosocial

Case Report: RA Patient Suffers Methotrexate-Induced Cutaneous Lesions

Nitasha Kumar, MD  |  August 16, 2019

Methotrexate (MTX) remains the predominant medication used by rheumatologists to treat rheumatoid arthritis (RA). Doses of 7.5–25 mg per week with daily folic acid are generally prescribed. Despite its common use, MTX must be prescribed cautiously given the potential adverse effects when taken incorrectly or without folic acid supplementation. Cases of MTX-induced cutaneous ulceration have…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Methotrexatetoxicity

IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  May 14, 2019

In a second response letter, the FDA has cited the onset and duration of intravenous meloxicam, a non-opioid pain treatment, as concerns that it fails to meet prescriber expectations…

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:CanadaFDAmeloxicamnon-opioid pain shotPainplaque psoriasisrizankixumabU.S. Food and Drug Administration (FDA)

Experts Discuss the Latest Precision Medicine Research

Susan Bernstein  |  February 18, 2018

SAN DIEGO—In just two decades, precision medicine has gone from futuristic concept to realistic toolbox for clinical physicians. At the 2017 ACR Clinical Research Conference on Nov. 3, the Precision Medicine in Rheumatic Diseases: Hopes and Challenges lecture featured rheumatologists and experts on genetics, genomics, pharmaco­genetics and big data who spoke about the latest research…

Filed under:Meeting ReportsRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:ACR/ARHP Annual MeetingArthritisbig dataGenetic researchgenomicsLupusPrecision MedicineRheumatoid arthritis

Valeant Prices Psoriasis Treatment at $3,500 Per Month

Reuters Staff  |  April 21, 2017

(Reuters)—Canadian drug maker Valeant Pharmaceuticals International Inc. said it had priced its recently approved plaque psoriasis treatment at $3,500 per month, ahead of an expected U.S. launch in the second half of 2017. Brodalumab (Siliq) is the lowest priced injectable biologic psoriasis treatment currently on the market, Valeant says. Drugmakers are facing intense criticism from…

Filed under:Drug Updates Tagged with:brodalumabcostsdrug costsPsoriasisValeant Pharmaceuticals

  • « Previous Page
  • 1
  • …
  • 59
  • 60
  • 61
  • 62
  • 63
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences